Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  New England Journal of Medicine

• Publication date

  2001-09-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJMOA011303PMID 11565517
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Statistical Methods for the Analysis of Biomedical Data

  2003cited by this paper
• [Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials].

  2001cited by this paper
• Diabetes trends in the U.S.: 1990-1998.

  2000cited by this paper
• Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury.

  2000cited by this paper
• Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration.

  2000cited by this paper
• Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

  2000cited by this paper
• The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group.

  2000cited by this paper
• Effect of angiotensin II antagonist eprosartan on hyperglycemia-induced activation of intrarenal renin-angiotensin system in healthy humans.

  2000cited by this paper
• Effects of Calcium-Channel Blockade in Older Patients with Diabetes and Systolic Hypertension

  1999cited by this paper
• Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators.

  1999cited by this paper
• Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study.

  1999cited by this paper
• The paradox of the low-renin state in diabetic nephropathy.

  1999cited by this paper
• Glomerular size-selective dysfunction in NIDDM is not ameliorated by ACE inhibition or by calcium channel blockade.

  1999cited by this paper
• Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39

  1998cited by this paper
• Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.

  1998cited by this paper
• In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation.

  1998cited by this paper
• Renal hemodynamic response to an angiotensin II antagonist, eprosartan, in healthy men.

  1997cited by this paper
• Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group.

  1996cited by this paper
• Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells.

  1994cited by this paper
• The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.

  1994cited by this paper
• Long-Term Stabilizing Effect of Angiotensin-Converting Enzyme Inhibition on Plasma Creatinine and on Proteinuria in Normotensive Type II Diabetic Patients

  1993cited by this paper
• Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition.

  1993cited by this paper
• The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.

  1993cited by this paper
• Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells.

  1992cited by this paper
• Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension.

  1986cited by this paper
• Discrete sequential boundaries for clinical trials

  1983cited by this paper

• Finerenone as an add-on treatment to conventional therapies for the patients with diabetic kidney disease

  2026cites this paper
• The Physician Innovator – stepping off the well-worn road to find new solutions

  2026cites this paper
• Connecting glycation and lipotoxicity to mitochondrial dysfunction in diabetic kidney disease: A 'tubulocentric' perspective.

  2026cites this paper
• Hirsutine Attenuates Renal Injury in Diabetic Kidney Disease by Regulating Th17 Cell Differentiation via the TGFβ/SMAD Pathway.

  2026cites this paper
• High expression of angiotensin-converting enzyme in macrophages exacerbates renal interstitial damage in diabetic mice.

  2026cites this paper
• Molecular pathways and emerging therapeutic targets in the pathogenesis of diabetic kidney disease.

  2026cites this paper
• Medical treatment for diabetic acute kidney disease from 2012 to 2024: advances, prescription trends, and future directions.

  2026cites this paper
• Evidence-Based CKD Prevention Strategies for Healthcare Professionals: Focusing on Primary and Secondary Prevention in Conservative Care.

  2026cites this paper
• Non-diabetic Kidney Disease in Type 2 Diabetes: From Kidney Biopsy to Precision Medicine

  2026cites this paper
• Microbiota-targeted modulation of the gut-kidney axis in diabetic kidney disease: Therapeutic advances and future perspectives.

  2026cites this paper
• Kidney Protection Options in 2025: Are Renin-Angiotensin System Inhibitors Still Needed?

  2026cites this paper
• Residual Renal Risk in Diabetic Nephropathy Despite Contemporary Therapies

  2026influential citation
• A clinical impact of apoptosis inhibitor of macrophage on feline chronic kidney disease.

  2026cites this paper
• Next-generation therapeutics for diabetic kidney disease.

  2026cites this paper
• Renin-angiotensin system inhibitor use and cardio-renal outcomes in non-proteinuric chronic kidney disease: a post-hoc analysis of the Frontier of Renal Outcome Modification-Japan study.

  2026cites this paper
• Total flavonoids from Abelmoschus manihot (L.) improve diabetes nephropathy by regulating the gut–kidney axis

  2026cites this paper
• Chronic Kidney Disease Progression Mechanisms: Why They Matter in an Era of Novel Kidney Protective Therapies.

  2026cites this paper
• [SEMERGEN position paper on chronic kidney disease].

  2026cites this paper
• Guideline-Directed Medical Therapy for Diabetic Kidney Disease: Advances in Primary and Secondary Prevention.

  2026cites this paper
• Hypertension in Diabetes: Numbers or Outcomes?

  2026cites this paper
• Maladie rénale chronique diabétique

  2026cites this paper
• The Japanese Society of Hypertension Guidelines for the management of elevated blood pressure and hypertension 2025 (JSH2025)

  2026cites this paper
• Machine learning based identification of key predictors and socioeconomic inequalities in the co-existence of diabetes and hypertension among Bangladeshi adults.

  2026cites this paper
• Pre-treatment estimated glomerular filtration rate trajectory modifies the renoprotective effect of finerenone in patients with chronic kidney disease associated with type 2 diabetes

  2026cites this paper
• Characteristics and cardio-renal outcomes in CKD patients receiving guideline-directed therapy: insights from DISCOVER CKD.

  2025cites this paper
• Comprehensive management of chronic kidney disease in the old population

  2025cites this paper
• Clinical Research Advances in Obesity and Cardiovascular Disorders

  2025cites this paper
• Efficacy of stem cell therapy for diabetic kidney disease: a systematic review and meta-analysis

  2025cites this paper
• Mechanisms of diabetic kidney disease and established and emerging treatments

  2025cites this paper
• Pillar Risk-Based Treatment for Chronic Kidney Disease in People With Type 2 Diabetes: A Narrative Review

  2025cites this paper
• Comparing CKD populations with T1D and T2D: a perspective based on the FINE-ONE and FIDELITY populations.

  2025cites this paper
• Comparative effectiveness and prescribing patterns of dapagliflozin vs empagliflozin in type 2 diabetes patients: a target trial emulation.

  2025cites this paper
• 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

  2025cites this paper
• Truth and Pitfalls of Evidence-Based Medicine

  2025cites this paper
• Should We Use Renin–Angiotensin-System Inhibitors As a First-Line Therapy for the Management of Hypertension in Patients Receiving Hemodialysis?

  2025cites this paper
• ACEi, ARB and ARNi for renal protection in heart failure patients.

  2025cites this paper
• Long-term Impact of Alpha-blockers on Renal Function - A Systematic Review and Meta-analysis.

  2025cites this paper
• In silico prediction of optimal multifactorial intervention in chronic kidney disease

  2025cites this paper
• KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV).

  2025cites this paper
• Involvement of dysregulated RNA binding protein and alternative splicing regulatory networks in diabetic nephropathy from type 2 albuminuric cohorts

  2025cites this paper
• Interconnected pathways and emerging therapies in chronic kidney disease and heart failure: A comprehensive review

  2025cites this paper
• Update on the pathophysiology and treatment of diabetic kidney disease: a narrative review

  2025cites this paper
• Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Lower eGFR Decline in Nondiabetic CKD Patients without Proteinuria

  2025cites this paper
• Dietary and Nutritional Strategies to Prevent Uremic Toxin Formation and Slow the Progression of Diabetic Kidney Disease

  2025cites this paper
• The Upcoming Challenge of Aging and Chronic Kidney Disease

  2025cites this paper
• Prognosis After >50% Decline in eGFR in Heart Failure Patients: A Nationwide Real-World Study.

  2025cites this paper
• Long-Term Effect of Semaglutide on the Glomerular Filtration Rate Slope in High-Risk Patients with Diabetic Nephropathy: Analysis in Real-World Clinical Practice

  2025cites this paper
• Expert Perspectives on Incorporating GLP-1 RA in Diabetes and Chronic Kidney Disease - Challenges and Opportunities.

  2025cites this paper
• Association of British Clinical Diabetologists and UK Kidney Association Joint Clinical Practice Guidelines for the Pharmacological Management of Hyperglycemia in Adults With Type 2 Diabetes Mellitus and CKD

  2025cites this paper
• Trends and Disparities in Hypertension-Related Mortality among Adults with Obesity in the United States from 2000-2023.

  2025cites this paper
• 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

  2025cites this paper
• 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

  2025cites this paper
• Gender differences in the prescription of SGLT2 inhibitors in chronic kidney disease: A real‐world database study

  2025cites this paper
• Kidney Dysfunction Following Gestational Diabetes Mellitus.

  2025cites this paper
• Factors affecting disease progression in early-stage chronic kidney disease in a multi-ethnic, southeast Asian primary care population

  2025cites this paper
• Beyond lipids: fenofibrate in diabetic retinopathy and nephropathy.

  2025cites this paper
• Diabetic Kidney Disease: From Pathophysiology to Regression of Albuminuria and Kidney Damage: Is It Possible?

  2025cites this paper
• Irbesartan in Hypertensive Non Diabetic Advanced Chronic Kidney Disease: Comparative Study With Losartan

  2025cites this paper
• COMPARATIVE EVALUATION OF SPORT-BASED EXERCISE MODALITIES FOR REDUCING ARTERIAL HYPERTENSION: A LITERATURE REVIEW

  2025cites this paper
• Multi-Center Health Informatics to Examine the Implementation of Guideline-Directed Medical Therapy in Chronic Kidney Disease

  2025cites this paper
• Unlocking Novel Therapeutic Potential of Angiotensin II Receptor Blockers

  2025cites this paper
• Multidisciplinary Delphi study on residual risk in patients with chronic kidney disease and type 2 diabetes mellitus.

  2025cites this paper
• Low Achieved Systolic Blood Pressure Related to Kidney Protection in Diabetic and Non-Diabetic High-Risk Hypertensive Patients

  2025cites this paper
• Renin Angiotensin Inhibition and Lower Risk of Kidney Failure in Patients with Heart Failure: Subtitle: RAS inhibition and kidney failure in heart failure.

  2025cites this paper
• Higher Risk of Kidney Failure Associated with Angiotensin Receptor Blockers Versus ACE Inhibitors in Patients with Heart Failure.

  2025cites this paper
• Cardiovascular and renal outcomes between sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors in patients with chronic kidney disease stages 4 and 5: a population-based study.

  2025cites this paper
• Benefits of Sodium-Glucose Cotransporter-2 Inhibitors with Renin-Angiotensin System Blockers in Type-2 Diabetes: A Cohort Analysis

  2025cites this paper
• SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application

  2025cites this paper
• The diagnostic status of chronic kidney disease in a real-world database in Japan: CHECK-CKD

  2025cites this paper
• 2025 Clinical Practice Guidelines for Diabetes Management in Korea: Recommendation of the Korean Diabetes Association

  2025cites this paper
• Using guideline-directed medical therapies to improve kidney and cardiovascular outcomes in patients with chronic kidney disease.

  2025cites this paper
• Decoding the efficacy and safety profiles of anti-hypertensive agents by targeting RAAS: A systematic review and meta-analysis of clinical trials

  2025cites this paper
• Cardiovascular-kidney-metabolic syndrome and treatment advances: a narrative review.

  2025cites this paper
• Serositis as an indicator of poor prognosis in pediatric systemic lupus erythematosus

  2025cites this paper
• Optimizing renin-angiotensin-aldosterone inhibition in advanced chronic kidney disease: balancing benefits and risks.

  2025cites this paper
• Urine Measurements of the Renin-Angiotensin System-Regulated Proteins Predict Death and Graft Loss in Kidney Transplant Recipients Enrolled in a Ramipril versus Placebo Randomized Controlled Trial.

  2025cites this paper
• Rationale and Design of NUDGE-CKD: A Nationwide Randomized Factorial Trial of Electronic Nudges for Increasing Guideline-Directed Medical Therapy in Chronic Kidney Disease.

  2025cites this paper
• Initiating renin–angiotensin system inhibitors in chronic kidney disease

  2025cites this paper
• Serum midkine level and its association with subclinical coronary artery calcification and carotid atherosclerosis in chronic kidney disease

  2025cites this paper
• Evaluating chronic kidney disease in Spanish people with diabetes: A study from internal medicine clinics.

  2025cites this paper
• The interplay between heart failure and chronic kidney disease

  2025influential citation
• Innovative therapeutics for renoprotection: Where we are.

  2025cites this paper
• Aldosterone-Related Cardiovascular Disease and Benefits of Mineralocorticoid Receptor Antagonists in Clinical Practice

  2025cites this paper
• Finerenone: Potential Clinical Application Across the Spectrum of Cardiovascular Disease and Chronic Kidney Disease

  2025cites this paper
• Discontinuing renin-angiotensin system inhibitors after incident hyperkalemia and clinical outcomes: target trial emulation

  2025cites this paper
• Chronic Kidney Disease in Diabetes: A Clinical Practice Guideline.

  2025cites this paper
• Improvement in the detection, diagnosis, and early treatment of chronic kidney disease in Spain. The IntERKit project.

  2025cites this paper
• The Future of Chronic Kidney Disease Treatment: Combination Therapy (Polypill) or Biomarker-Guided Personalized Intervention?

  2025cites this paper
• Use of eGFR Slope Thresholds as End Point Components in a Kidney Disease Progression Hierarchical Composite End Point.

  2025cites this paper
• Preoperative proteinuria as a novel biomarker for predicting postoperative renal insufficiency after nephrectomy for renal cell carcinoma: a systematic review and meta-analysis

  2025cites this paper
• Comparative Effects of Dulaglutide and Semaglutide on Renal Function Decline and Proteinuria Reduction in Diabetic Patients: A Retrospective Cohort Study

  2025cites this paper
• Gut microbiota implication in diabetic kidney disease: mechanisms and novel therapeutic strategies

  2025cites this paper
• Current Strategies for Preventing Diabetic Kidney Disease

  2025cites this paper
• Cardiovascular-Kidney-Metabolic Health: Definition, Staging, Risk Assessment, and Therapeutic Considerations.

  2025cites this paper
• Targeting NF-κB in diabetic nephropathy: exploring the therapeutic potential of phytoconstituents

  2025cites this paper
• Effects of RAS and SGLT2 inhibitors alone or in combination on end-stage kidney disease and/or all-cause death in patients with both diabetes and hypertension: a nationwide cohort study

  2025cites this paper
• Prescription of ACE-Is/ARBs in patients with cardio-renal disease: a multicenter retrospective cohort study from the REPOSI registry

  2025cites this paper
• A Primary Care Guide to the Screening and Pharmacologic Management of Chronic Kidney Disease in People Living With Type 2 Diabetes

  2025cites this paper
• Chronic kidney disease in the primary care setting: A narrative review

  2025cites this paper
• Leveraging complementary multi-omics data integration methods for mechanistic insights in kidney diseases

  2025cites this paper